<DOC>
	<DOCNO>NCT00773591</DOCNO>
	<brief_summary>This proof-of-concept study ass potential benefit botulinum toxin patient sleep-related breathing disorder .</brief_summary>
	<brief_title>Effect NT 201 ( Botulinum Neurotoxin Type A Free Complexing Proteins ) Sleep-related Breathing Disorders</brief_title>
	<detailed_description>Mono-center , double-blind , 1:1 randomize , placebo-controlled trial 18 treated patient , 9 patient per group . Patients randomly assign treatment NT 201 placebo ratio 1:1 . In addition , within treatment group patient randomly assign injection leave right soft palate . Primary variable : Comparison ratio snoring time sleep time ( Snoring Index ) . Other secondary variable analyse .</detailed_description>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<criteria>1 . Male female outpatient least 18 year age . 2 . Patient understand nature study provide write informed consent prior protocolspecific procedure . 3 . Patients suffer sleeprelated breathe disorder least 3 month prior study start seek help snoring . 4 . NonREM RDI ≤ 25/h ( accord Medicare Criteria ) baseline PSG . 5 . AHI ≤ 10/h baseline PSG . 6 . Snoring Index ≥ 15 baseline PSG . 1 . Patients know hypersensitivity : botulinum neurotoxin type ; excipients ( human albumin , sucrose ) . 2 . Patients upper respiratory tract pathology assess ear , nose , throat [ ENT ] specialist . 3 . Patients generalized disorder muscle activity ( e.g . myasthenia gravis , LambertEaton syndrome ) . 4 . Patients bleed disorder type and/or receive anticoagulant therapy . 5 . Patients profound sleep disorder ( pathological number duration episodes hypopnea apnea ) , upper airway resistance syndrome [ UARS ] , obstructive sleep apnea syndrome [ OSAS ] . 6 . Obese patient ( BMI ≥ 30 ) . 7 . Presence concomitant disease : severe unstable cardiovascular ( e.g . severe angina pectoris , post myocardial infarction ventricular extra systole ) , pulmonary , endocrine disease ; clinically relevant renal hepatic disease dysfunction ; hematological disorder ; clinically relevant medical condition could increase risk study participant ; malignant disease kind previous 5 year except successfully treat skin ( basal squamous cell ) cancer ; amyotrophic lateral sclerosis disease result peripheral neuromuscular dysfunction ; risk develop angle closure glaucoma ; alcohol , drug , medication abuse within past year ; severe psychiatric neurological disorder ; acute infection pharynx . 8 . Patients likely need concomitant medication follow : 4aminochinolines ; aminoglycosides spectinomycin , medical product interfere neuromuscular transmission , e.g . tubocurarinetype muscle relaxant ; daily psychotropic medication ; regular intake onset hypnotic , e.g . benzodiazepine , chloralhydrate combination , barbiturate ( except mild phytotherapeutics , e.g . valerian , hop combination ) ; antisnoring product course study foam , dental device . 9 . Pregnant nursing woman , woman childbearing potential use willing continue use medically reliable method contraception entire study duration , oral , injectable , implantable contraceptive , intrauterine contraceptive device , unless surgically sterilized/ hysterectomized . 10 . Participation clinical study within last 30 day prior start study . 11 . Patients employee , relative spouse investigator , staff investigational site sponsor CRO . 12 . Any donation germ cell , blood , organ , bone marrow course study . 13 . Patients expect noncompliant and/or cooperative . 14 . Patients contractually capable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Sleep-related breathing disorder</keyword>
	<keyword>Snoring</keyword>
</DOC>